Amid mutual accusations between China and the U.S. of violating the Trump-era trade deal, both the Dow Jones Industrial Average (DJI) and S&P 500 (SPX) remain largely stagnant. Although it is yet to be seen what impact the trade deal will exert, yesterday’s OECD report did not appear to be bullish. The Organization for Economic Cooperation and Development (OECD) projects a global slowdown to 2.9% in 2025/26 from 3.3% growth in 2024.
Specifically for the US, GDP is forecasted to decline from 2.8% in 2024 to 1.6% in 2025 and 1.5% in 2026. Anticipating this development, many analysts are switching their stock ratings. Let’s examine which companies received a positive rating, either upgraded from neutral to buy or from hold to buy, along with the one company that received a neutral rating.
Kymera Therapeutics
Year-to-date, Kymera Therapeutics (NASDAQ:KYMR) stock is up nearly 13%, but surged 64% over the week. The sudden valuation came on the heels of the STAT6 degrader (KT-621) trial, showing the oral drug’s superb efficacy. Specifically, by degrading STAT6 transcription factor, KT-621 reduces inflammatory responses which in turn overstimulate the production of disease-related cytokines.
As signal-carrying proteins, cytokines are vital in regulating immune and inflammatory responses, ultimately defending the body against both abnormal cells and external pathogens. KT-621 exceeded Kymera’s expectations, able to achieve over 90% STAT6 degradation above 1.5 mg dosing.
Equally importantly, the side effects of the drug appear negligible, undifferentiated from placebo. By reducing Th2-driven inflammation, KT-621 has the potential to treat a host of conditions, from allergic reactions to chronic inflammatory diseases.
Presently priced at $43.58 per share, WSJ’s forecasting points to $61.63 as the average KYMR price target with $51 as the bottom and $97 as the ceiling. While UBS analysts maintain their $70 target, B.Riley Securities have upgraded the stock from neutral to buy, at 60$.
Likewise, Morgan Stanlely upgraded KYMR stock from equal-weight to overweight, at $79, signaling the expectation to outperform the market average.
JP Morgan upgraded the stock from neutral to overweight, placing the Pinterest (NYSE:PINS) stock target at $40. Against its current price of $33.13, the average PINS price target is $40.16, with the bottom at $25 and ceiling of $50 per share. Only one analyst recommends selling, 7 prefer holding while 32 analysts recommend buying.
Over a one-year period, PINS stock is down nearly 20%, but up 24% over the last month. Serving as a visual discovery platform targeting females aged 18 to 49, Pinterest primarily makes money through advertising (Promoted Pins) as native ads in users’ feeds and search results.
On May 8th, the company delivered Q1 2025 earnings, showing 10% year-over-year growth in global users to 570 million monthly active users. Average revenue per user increased by 5%, resulting in a YoY revenue increase of 16% to $855 million. For Q2, the company anticipates even greater revenue within the $960 – $980 million range, above analyst expectations of $966 million.
By integrating shopping and advertising in a single platform, it appears that Pinterest is becoming a “more resilient business than ever before,” according to the company’s CEO Bill Ready.
ASML Holding N.V.
Dutch ASML (NASDAQ:ASML) is the world’s semiconductor chokepoint, as the only provider of extreme ultraviolet (EUV) lithography machines, necessary for manufacturing all advanced chips designed by companies like Nvidia (NASDAQ:NVDA) or AMD (NASDAQ:AMD). As such, ASML is heavily scrutinized by the US in its effort to curtail China’s AI advancement.
Over a year, the ongoing trade war between China and the US resulted in the company’s ~$130 billion market value shrinkage. This aligns with a mid-April report showing ASML having lower-than-expected net bookings in Q1 2025.
Most recently, Barclays (LON:BARC) downgraded ASML stock from overweight to equal weight, meaning that the company is expected to perform in line with the market average. However, investors should still keep an eye on ASML at any market dip. As we have maintained all along, AI is not a bubble, but a new layer of global governance and economy, evidenced most recently by Saudi Arabia’s PPP push.
Taking into account all analyst inputs, the average ASML price target is $857 vs the current price of $747.39 per share, giving an overall overweight rating in contrast to Barclays’ shift. The bottom outlook is $680 while the ceiling target for ASML stock is $1,104 per share.
***
Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.
This article was originally published on The Tokenist. Check out The Tokenist’s free newsletter, Five Minute Finance, for weekly analysis of the biggest trends in finance and technology.